Company: MIRM
Filing Date: 2025-05-07
Form Type: 10-Q
Source: 0001759425-25-000032
Chunk: 332

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-05-07
Form: 10-Q
Item: Part I, Item 1
Chunk 332
---
Item 1. Financial Statements.

Mirum Pharmaceuticals, Inc.

Condensed Consolidated Balance Sheets

(Unaudited)

(In thousands, except share and per share data)

 March 31,2025December 31,2024 (Note 2) AssetsCurrent assets:Cash and cash equivalents$211,822 $222,503 Short-term investments65,852 57,812 Accounts receivable95,852 78,286 Inventory22,418 22,403 Prepaid expenses and other current assets14,874 11,784 Total current assets410,818 392,788 Restricted cash425 425 Long-term investments20,912 12,526 Property and equipment, net1,108 1,139 Operating lease right-of-use assets7,663 8,675 Intangible assets, net243,845 249,819 Other assets5,474 5,382 Total assets$690,245 $670,754 Liabilities and Stockholders’ EquityCurrent liabilities:Accounts payable$11,639 $14,618 Accrued expenses and other current liabilities115,938 111,933 Total current liabilities127,577 126,551 Operating lease liabilities, noncurrent7,003 7,972 Convertible notes payable, net, noncurrent308,509 308,082 Other liabilities13,900 2,509 Total liabilities456,989 445,114 Commitments and contingenciesStockholders’ equity:Preferred stock, $0.0001 par value; 10,000,000 shares authorized, and no shares issued and outstanding as of March 31, 2025 and December 31, 2024— — Common stock, $0.0001 par value; 200,000,000 shares authorized; 49,451,223 and 48,338,096 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively5 5 Additional paid-in capital892,367 870,189 Accumulated deficit(658,858)(644,181)Accumulated other comprehensive loss(258)(373)Total stockholders’ equity233,256 225,640 Total liabilities and stockholders’ equity$690,245 $670,754 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

1

Table of Contents